| Autor: |
Conceição Gomes Nascimento K; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Gonçalves Lima É; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Mota Nunes Z; Laboratory of Molecular Genetics (LAGEM), Department of Engineering and Environment, Federal University of Paraiba, João Pessoa 58297-000, Brazil., Rêgo Barros Júnior M; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., de Aragão Batista MV; Laboratory of Molecular Genetics and Biotechnology (GMBio), Department of Biology, Federal University of Sergipe, São Cristóvão 49100-000, Brazil., Lucena Araujo AR; Department of Biophysics and Radiobiology, Federal University of Pernambuco, Recife 50670-901, Brazil., da Costa Silva Neto J; Department of Histology, Federal University of Pernambuco, Recife 50670-901, Brazil., Simas Chagas B; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil., Almeida Diniz Gurgel AP; Laboratory of Molecular Genetics (LAGEM), Department of Engineering and Environment, Federal University of Paraiba, João Pessoa 58297-000, Brazil., de Freitas AC; Laboratory of Molecular Studies and Experimental Therapy (LEMTE), Department of Genetics, Federal University of Pernambuco, Recife 50670-901, Brazil. |
| Abstrakt: |
This study evaluated the presence of Human Papillomavirus (HPV) DNA in the cervix and peripheral blood of women with cervical intraepithelial neoplasia (CIN I, II, and III) and healthy individuals. Overall, 139 paired peripheral blood and cervix samples of healthy women and women with CIN I, II, and III ( n = 68) were tested for HPV DNA by using standard procedures. Polymerase chain reaction (PCR) sequencing determined HPV types. Quantification of HPV16 E6 and E2 genes was performed to determine viral load and physical state. HPV DNA was detected in the cervix (21.1% in healthy individuals; 48.8-55.5% in CIN patients), blood (46.4% in healthy individuals; 44.1-77.7% in CIN patients) and paired peripheral blood and cervix samples (24% in healthy individuals; 32.5-44.4% in CIN patients). The most frequent types found in the cervix were HPV16, 18, 31, 33, 58, and 70, while HPV16, 18, 33, 58, and 66 were the most frequent types found in the blood. HPV DNA in the cervix was associated with previous sexually transmitted infections (STIs) ( p = 0.023; OR: 2.978; CI:1.34-7.821), HPV DNA in the blood ( p = 0.000; OR: 8.283; CI:3.700-18.540), and cervical lesions (CIN I/II or III) ( p = 0.007). Binomial logistic regression showed that HPV DNA in the blood ( p = 0.000; OR: 9.324; CI:3.612-24.072) and cervical lesions ( p = 0.011; OR: 3.622; CI:1.338-9.806) were associated with HPV DNA in the cervix. However, we did not find an association between HPV DNA in the blood and cervical lesions ( p = 0.385). Our results showed that only HPV DNA found in the cervix was associated with cervical lesions. |
